Clinical study: Fish oil lipid emulsion reduces the morbidity of intestinal failure- associated liver disease among newborns?

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100043401

Enrollment

Unknown

Registered

2021-02-14

Start date

2021-03-01

Completion date

Unknown

Last updated

2021-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

intestinal failure- associated liver disease

Interventions

Group1:Medium-long chain fat emulsion (3g/kg)

Group2:SMOF (3g/kg)

Group3:Fish oil lipid emulsion (2g/kg)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Newborns after gastrointestinal tract surgery; 2. Estimated time required for intravenous nutritional support is more than 2 weeks;

Exclusion criteria

Exclusion criteria: 1. Neonates diagnosed as congenital hepatobiliary diseases; 2. Neonates with genetic metabolic diseases;

Design outcomes

Primary

Measure	Time frame
serum direct bilirubin;	—

Secondary

Measure	Time frame
weight;length;head circumference;cytokines;Fatty acid composition;coagulation function;Brain MRI;Total body movement GMS quality assessment;Test of Infant Motor Performance;intestinal microecology;Bayley Test;	—

Countries

China

Contacts

Public ContactZhang Li

zhanglihk@126.com+86 18180609893

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026